Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Reaches CNY 278.24

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.62% on February 25, 2026. The stock reached an intraday low of CNY 278.24, reflecting a challenging trading session. Over the past week, the stock has decreased by 2.75%, contrasting with a slight gain of 0.41% in the China Shanghai Composite index. In terms of longer-term performance, Sichuan Biokin has shown a year-to-date decline of 13.62%, while the broader market has gained 2.85%. Despite these recent setbacks, the company has demonstrated significant growth over the past three years, with a remarkable increase of 268.94% in stock value, outperforming the China Shanghai Composite during this period. Financial metrics indicate that the company is facing difficulties, with net sales for the last nine months declining by 63.52% and a net profit of CNY -500.37 million, reflecting a growth rate of -112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million. As a large-cap player in the pharmaceuticals and biotechnology sector, Sichuan Biokin continues to navigate a complex market landscape.